MARKET

PRTA

PRTA

Prothena Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.80
+0.56
+5.47%
Closed 16:00 11/19 EST
OPEN
11.92
PREV CLOSE
10.24
HIGH
11.96
LOW
10.76
VOLUME
297.83K
TURNOVER
--
52 WEEK HIGH
14.77
52 WEEK LOW
6.71
MARKET CAP
430.88M
P/E (TTM)
-5.4895
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PRTA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PRTA News

  • Prothena up 8% on Evercore upgrade
  • Seeking Alpha - Article.18h ago
  • Prothena (NASDAQ:PRTA) Is In A Good Position To Deliver On Growth Plans
  • Simply Wall St..18h ago
  • Benzinga's Top Upgrades, Downgrades For November 19, 2019
  • Benzinga.19h ago
  • Evercore downgrades bluebird bio and Clovis in premarket analyst action
  • Seeking Alpha - Article.21h ago

More

Industry

Biotechnology & Medical Research
+2.16%
Pharmaceuticals & Medical Research
+0.78%

Hot Stocks

Name
Price
%Change

About PRTA

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
More

Webull offers Prothena Corporation PLC (PRTA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.